Posted by Michael Wonder on 24 Oct 2022
Acumen’s ACU193, an anti-amyloid beta oligomer antibody, granted FDA fast track designation for Alzheimer's disease
24 October 2022 - Acumen Pharmaceuticals today announced that ACU193, the first clinical stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers, has been granted fast track designation for the treatment of early Alzheimer’s disease by the US FDA.
ACU193 is currently being studied in the Phase 1 INTERCEPT-AD trial designed to assess safety and proof of mechanism of ACU193.
